A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
PHASE2
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL)...
Status
Completed
Location
The University of Arizona Cancer Center - North Campus ( Site 2216)
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
PHASE1
This is a phase I/II multicenter, open-label umbrella platform study that w...
Status
Completed
Location
Liga Norte Riograndense Contra o Câncer ( Site 2303)
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
PHASE1
This is a Phase 1/2, multicenter, randomized, open-label umbrella platform ...
Status
Recruiting
Location
University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927)